Advertisement

Volume 130, Issue 22

Cover Figure: PD-L1+ macrophages protect Reed-Sternberg cells from immune attack in the HL microenvironment. See the article by Carey et al.

WASHINGTON, November 30, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Carey and colleagues use elegant immunofluorescence and digital image analysis to demonstrate that PD-L11cells in the tumor microenvironment of Hodgkin lymphoma are predominantly macrophages that protect Reed-Sternberg cells from CD41 T-cell attack. These cells are the target of therapeutic PD-1 blockade.

Clonality in context: hematopoietic clones in their marrow environment
In a Perspective, Cooper and Young discuss their view of clonal hematopoiesis of indeterminate potential, offering an interpretation which suggests that many of these mutations are clinically benign. Using chemotherapy, bone marrow failure, and aging as models, they caution against overinterpretation and, more importantly, overtreatment of clonal hematopoiesis.

Gemtuzumab ozogamicin for acute myeloid leukemia
In the wake of the reapproval of gemtuzumab ozogamicin for the treatment of adults with acute myeloid leukemia, Appelbaum and Bernstein summarize the complex sequence of events by which the US Food and Drug Administration approved, disapproved, and reapproved the first antibody-drug conjugate for human use.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

and

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Two articles describe promising clinical results with the BCL2 inhibitor venetoclax as targeted therapy for multiple myeloma. Moreau and colleagues report outcomes with venetoclax combined with bortezomib and steroids for relapsed/refractory multiple myeloma (rrMM), and Kumar et al report on efficacy of single-agent venetoclax in rrMM. Venetoclax is especially successful in patients with high-BCL2-expressing tumors and patients with t(11;14).

Advances in the diagnosis and treatment of Von Willebrand disease
In an article copublished with the Hematology 2017 American Society of Hematology Education Program, Sharma and Flood review the new options for the diagnosis and treatment of von Willebrand disease.

Targeting novel mechanisms of pain in sickle cell disease
In an article copublished with the Hematology 2017 American Society of Hematology Education Program, Tran and colleagues review new developments in the understanding of the pathophysiology of sickle cell disease–related pain and how these concepts can inform novel therapeutic strategies.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.